Topiramat Kullanımına Bağlı Negatif Myoklonus; Nadir Bir Olgu Sunumu

Year 2017, Volume: 3 Issue: 3, 223 - 225, 01.01.2017

Öznur Bozkurt Şenay Haspolat Özgür Duman

Abstract

Epileptik negatif miyoklonus ENM çeşitli nörolojik hastalıklarla birlikte görülebilen spesifik olmayan epileptik özellikte motor bir bozukluktur. Öncesinde pozitif miyoklonusun izlenmediği, tonik kas aktivitesinin ani bir şekilde kesintiye uğramasıyla eş zamanlı olarak EEG’de epileptik anormal aktivitenin izlenmesi şeklinde tanımlanır. Epileptik negatif miyoklonus ENM ; çocukluk çağında sık görülen bening rolandik epilepsi gibi fokal epilepsilere eşlik edebildiği gibi, tedavide kulanılan antiepileptik ilaçlarla da ilişkili oluşabilmektedir. Sıklıkla karbamazepin kullanımına bağlı olarak bildirilmektedir, fakat okskarbazepin, fenitoin ve lamotrigin kullanımı sonrası da görülebilmektedir. Tedavide kullanılan antiepileptik ilaçların nöbet karakterini değiştirebildiği, bazen de nöbet sayı ve sıkılığını artırabildiği bilinmektedir. Bu yazıda, fokal motor nöbetleri sebebiyle takip edilen bir hastada; topiramat kullanımı sırasında gelişen epileptik negatif miyoklonustan bahsedilecektir

Keywords

Miyoklonus, Epileptik Negatif Miyoklonus, Topiramat

Negative Myoclonus Due to Topiramate Treatment: A Rare Case Presentation

Abstract

Epileptic negative myoclonus ENM is an unspecific motor disorder that can characterize a variety of neurological conditions. Epileptic negative myoclonus ENM is defined as an interruption of tonic muscle activity, which is time-locked to an epileptic EEG abnormality, without evidence of an antecedent positive myoclonia in the agonist–antagonist muscles. Some reports have demonstrated induction or worsening of ENM due to antiepileptic drugs in children suffering from focal epilepsies. Carbamazepine is the drug more frequently involved but other drugs such as oxcarbazepine, phenytoin and lamotrigine have been reported to be able to induce or aggravate ENM. It is well known that antiepileptic drugs may aggravate or precipitate seizures. This paradoxical reaction to a given antiepileptic drug is defined by the presence of increased seizure frequency or the appearance of new seizure types after its administration and full remission following its discontinuation. Here we present an epileptic child who had negative myoclonus after initiation of topiramate treatment

Keywords

Myoclonus, Epileptic Negative Myoclonus, Topiramate

References

• Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol Clin 2006;36(5-6):337-43.
• Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42: 796-803.
• Parmeggiani L, Seri S, Bonanni P, Guerrini R. Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol 2004;115(1):50-8.
• Nanba Y, Maegaki Y. Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Benign childhood epilepsy with centrotemporal spikes. Pediatr Neurol 1999;21(3): 664-75.
• Cirignotta F, Lugaresi E. Partial motor epilepsy with ‘‘negative myoclonus”. Epilepsia 1991;32(1):54-8.
• Guerrini R, Dravet C, Genton P, Bureau M, Roger J, Rubboli G, Tassinari CA. Epileptic negative myoclonus. Neurology 1993; 43(6): 1078-83.
• Shirasaka Y, Mitsuyoshi I. A case of epileptic negative myoclonus: Therapeutic considerations. Brain & development 1999;21(3):209-12.
• Parmeggiani L, Seri S, Bonanni P, Guerrini R. Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol 2004;115(1):50-8.
• Yang Z, Liu X, Qin J, Zhang Y, Bao X, Chang X, Wang S, Wu Y, Xiong H: A study on epileptic negative myoclonus in atypical benign partial epilepsy of childhood. Brain & Development 2009, 31(4):274-81.
• Oguni H, Uehara T, Tanaka T, Sunahara M, Hara M, Osawa M. Dramatic effect of ethosuximide on epileptic negative myoclonus: Implications for the neurophysiological mechanism. Neuropediatrics 1998, 29(1):29-34.
• Capovilla G, Beccaria F, Veggiotti P, Rubboli G, Meletti S, Tassinari CA: Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. Journal of Child Neurology 1999, 14(6):395-400.
• Gelisse P, Crespel A, Genton P, Baldy-Moulinier M: Dra- matic effect of levetiracetam on epileptic negative myoc- lonus. Acta Neurologica Scandinavica 2003, 107(4):302- 3.